Lung cancer trial: does double immunotherapy beat single?
NCT ID NCT06364917
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study is for people with a type of advanced lung cancer that lacks the PD-L1 marker. It compares standard treatment (one immunotherapy drug plus chemo) to a stronger approach (two immunotherapy drugs plus chemo). The goal is to see if the double therapy clears cancer DNA from the blood faster. 24 adults are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.